In last trading session, Leap Therapeutics Inc (NASDAQ:LPTX) saw 1.13 million shares changing hands with its beta currently measuring -0.26. Company’s recent per share price level of $0.28 trading at $0.0 or 0.79% at ring of the bell on the day assigns it a market valuation of $11.70M. That closing price of LPTX’s stock is at a discount of -1610.71% from its 52-week high price of $4.79 and is indicating a premium of 21.43% from its 52-week low price of $0.22.
For Leap Therapeutics Inc (LPTX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Leap Therapeutics Inc (NASDAQ:LPTX) trade information
Upright in the green during last session for gaining 0.79%, in the last five days LPTX remained trading in the red while hitting it’s week-highest on Monday, 06/23/25 when the stock touched $0.28 price level, adding 36.0% to its value on the day. Leap Therapeutics Inc’s shares saw a change of -85.30% in year-to-date performance and have moved -25.04% in past 5-day. Leap Therapeutics Inc (NASDAQ:LPTX) showed a performance of -22.57% in past 30-days.
Wall Street analysts have assigned a consensus price target of 5.5 to the stock, which implies a rise of 94.91% to its current value. Analysts have been projecting 5.5 as a low price target for the stock while placing it at a high target of 5.5. It follows that stock’s current price would drop -1864.29% in reaching the projected high whereas dropping to the targeted low would mean a loss of -1864.29% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 34.28% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 38.67% while estimates for its earnings growth in next 5 years are of 32.77%.
Leap Therapeutics Inc (NASDAQ:LPTX)’s Major holders
BALYASNY ASSET MANAGEMENT L.P. is the top institutional holder at LPTX for having 3.1 million shares of worth $6.08 million. And as of 2024-06-30, it was holding 7.9238 of the company’s outstanding shares.
The second largest institutional holder is SAMSARA BIOCAPITAL, LLC, which was holding about 2.44 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.2428 of outstanding shares, having a total worth of $4.79 million.
